Date
|
Update
|
06 August 2019 - 04 September 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
22 October 2018
|
The company that is developing fostamatinib have shared confidential information with NICE. As a result the Institute will not be progressing with the scoping exercise at this current time. Consequently the consultation on the draft scope will now be closed early.
If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk
|